We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
APO-PACLITAXEL, PACLITAXEL APOTEX (Apotex Pty Ltd)
Product name
APO-PACLITAXEL, PACLITAXEL APOTEX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
253 working days (255)
Active ingredients
paclitaxel
Registration type
New generic medicine
Indication
Metastatic Breast Cancer
Albumin-bound APO-PACLITAXEL, PACLITAXEL APOTEX (powder for injection) are indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy.